Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beam Therapeutics Inc.BEAM · Entity 4227 | Director · CEO | June 29, 2026 | July 01, 2026 |
| Verve Therapeutics, Inc.VERV · Entity 11259 | Director | June 09, 2022 | June 13, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beam Therapeutics Inc.
Report date June 29, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,047,205 |
Ending reported balance
After 2026-06-30 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-06-29 · Exercise / conversion · Acquired 18,663 · Balance 1,065,868 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Row 2 · 2026-06-29 · Exercise / conversion · Acquired 6,337 · Balance 1,072,205 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Row 3 · 2026-06-29 · Sale · Disposed 13,421 · Balance 1,058,784 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.55 to $35.50, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 4 · 2026-06-29 · Sale · Disposed 11,579 · Balance 1,047,205 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.60 to $36.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 5 · 2026-06-30 · Exercise / conversion · Acquired 25,000 · Balance 1,072,205 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. Row 6 · 2026-06-30 · Sale · Disposed 23,100 · Balance 1,049,105 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.80 to $34.71, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 7 · 2026-06-30 · Sale · Disposed 1,900 · Balance 1,047,205 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.83 to $34.85, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.67 · Expires 2028-05-08 | Direct | 9 |
Reported balance
After 2026-06-29 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-06-29 · Exercise / conversion · Disposed 18,663 · Balance 9 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F6: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2028-07-13 | Direct | 230,804 |
Reported balance
After 2026-06-29 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-06-29 · Exercise / conversion · Disposed 6,337 · Balance 230,804 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F7: On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2028-07-13 | Direct | 205,804 |
Reported balance
After 2026-06-30 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-06-30 · Exercise / conversion · Disposed 25,000 · Balance 205,804 F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025. F7: On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter. |
| Common StockSEC Table I · non-derivative | IndirectBy John M. Evans, III 2018 Irrevocable Trust | 103,000 |
Reported balance
Holding disclosure · report date 2026-06-29 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 103,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options were exercised and the shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.55 to $35.50, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.60 to $36.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.80 to $34.71, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.83 to $34.85, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares.
F7: On July 13, 2018, the Reporting Person was granted an option to purchase 539,645 shares of common stock, which vested as to 25% of the underlying shares on January 8, 2019 and in 36 equal monthly installments thereafter.
Verve Therapeutics, Inc.
Report date June 09, 2022 · Filed June 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.04 · Expires 2032-06-08 | Direct | 15,500 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 15,500 · Balance 15,500 F1: This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the "Vesting Commencement Date") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the "Vesting Commencement Date") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 21, 2021 Filed Apr 23, 2021 20:45 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,463 | $67.90 | $99,337.70 |
DisclosureSEC source: 0000899243-21-016869 · doc4.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038,966 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · price: These shares were sold in multiple transactions ranging from $67.67 to $68.00 inclusive. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 21:20 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 138,750 | $0.00 Strike: $80.04 | $0.00 |
DisclosureSEC source: 0000899243-21-014620 · doc4.xml · derivative · entry 3 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,750 Underlying: Common Stock · 138,750 shares Expires 2031-03-31 F2 · derivative.exercise_date: The stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with the Company through each vesting date. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 21:20 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantCommon Stock | 69,375 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-014620 · doc4.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,040,332 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Company's 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the Company through each vesting date. Read SEC document |
| March 31, 2021 Filed Apr 12, 2021 23:29 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | OtherCommon Stock | 32 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-015558 · doc4.xml · nonDerivative · entry 3 Evans John M. · CIK 0001786304 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,040,429 F1 · kind: Distribution of BEAM common stock held by ARCH Venture Fund IX, L.P. to its partners for no consideration. Read SEC document |
| March 22, 2021 Filed Apr 12, 2021 23:29 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | OtherCommon Stock | 32 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-015558 · doc4.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,040,397 F1 · kind: Distribution of BEAM common stock held by ARCH Venture Fund IX, L.P. to its partners for no consideration. Read SEC document |
| March 18, 2021 Filed Apr 12, 2021 23:29 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | OtherCommon Stock | 33 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-015558 · doc4.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,040,365 F1 · kind: Distribution of BEAM common stock held by ARCH Venture Fund IX, L.P. to its partners for no consideration. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:31 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,666 | $89.41 | $148,957.06 |
DisclosureSEC source: 0000899243-21-000136 · doc4.xml · nonDerivative · entry 8 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 970,957 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F9 · price: These shares were sold in multiple transactions ranging from $89.00 to $89.66 inclusive. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:31 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,121 | $88.12 | $98,782.52 |
DisclosureSEC source: 0000899243-21-000136 · doc4.xml · nonDerivative · entry 7 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 972,623 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F8 · price: These shares were sold in multiple transactions ranging from $87.96 to $88.50 inclusive. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:31 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 504 | $86.79 | $43,742.16 |
DisclosureSEC source: 0000899243-21-000136 · doc4.xml · nonDerivative · entry 6 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973,744 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F7 · price: These shares were sold in multiple transactions ranging from $86.65 to $86.97 inclusive. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:31 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 7,196 | $86.21 | $620,367.16 |
DisclosureSEC source: 0000899243-21-000136 · doc4.xml · nonDerivative · entry 5 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974,248 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: These shares were sold in multiple transactions ranging from $85.63 to $86.60 inclusive. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:31 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,422 | $85.35 | $121,367.70 |
DisclosureSEC source: 0000899243-21-000136 · doc4.xml · nonDerivative · entry 4 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 981,444 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: These shares were sold in multiple transactions ranging from $84.63 to $85.58 inclusive. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:31 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 4,925 | $83.76 | $412,518.00 |
DisclosureSEC source: 0000899243-21-000136 · doc4.xml · nonDerivative · entry 3 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 982,866 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: These shares were sold in multiple transactions ranging from $83.19 to $84.07 inclusive. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:31 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 4,100 | $82.33 | $337,553.00 |
DisclosureSEC source: 0000899243-21-000136 · doc4.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 987,791 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: These shares were sold in multiple transactions ranging from $82.00 to $82.99 inclusive. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:31 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,366 | $81.14 | $110,837.24 |
DisclosureSEC source: 0000899243-21-000136 · doc4.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 991,891 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · price: These shares were sold in multiple transactions ranging from $81.00 to $81.46 inclusive. Read SEC document |
| April 16, 2020 Filed Aug 18, 2020 01:25 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionStock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000899243-20-022630 · doc4.xml · derivative · entry 3 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,345 Underlying: Common Stock · 115,000 shares Expires 2028-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested. Read SEC document |
| April 16, 2020 Filed Aug 18, 2020 01:25 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | Exercise / conversionCommon Stock | 115,000 | $1.03 | $118,450.00 |
DisclosureSEC source: 0000899243-20-022630 · doc4.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 993,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2020 Filed Sep 21, 2021 22:00 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 53,964 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0000899243-21-036822 · doc4a.xml · derivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,964 Underlying: Common Stock · 53,964 shares Expires 2029-02-13 F1 · security: On August 17, 2020, the reporting person filed a Form 4 which inadvertently omitted certain options held by the reporting person on such date (the "Original Form 4"). F4 · derivative.exercise_date: On February 13, 2019, the reporting person was granted an option to purchase 107,929 shares of common stock of the Company. The option award vests (i) fifty percent (50%) upon the Company achieving a certain development milestone related to base editing applications, and (ii) fifty percent (50%) upon the achievement of a closing price hurdle following the Company's IPO (which closing price hurdle has been achieved). The portion of the award subject to satisfaction of the Price Condition is scheduled to vest in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022. Upon the closing of the IPO, vesting of the portion of the option award subject to condition (ii) was tied only to the passage of time and the market price of the Company's securities and thus, 50% of the option award became reportable. The Original Form 4 failed to report the portion of the option award that became reportable upon the closing of the Company's IPO. Read SEC document |
| February 05, 2020 Filed Sep 21, 2021 22:00 UTC Amendment | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 99,336 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0000899243-21-036822 · doc4a.xml · derivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,336 Underlying: Common Stock · 99,336 shares Expires 2028-05-08 F1 · security: On August 17, 2020, the reporting person filed a Form 4 which inadvertently omitted certain options held by the reporting person on such date (the "Original Form 4"). F2 · derivative.exercise_date: On May 8, 2018, the reporting person was granted an option to purchase 198,672 shares of common stock of Beam Therapeutics Inc. (the "Company"). The option award vests (i) fifty percent (50%) upon the Company achieving a certain development milestone related to base editing applications, and (ii) fifty percent (50%) upon the achievement of a closing price hurdle following the Company's initial public offering ("IPO") (which closing price hurdle has been achieved) (the "Price Condition"). The portion of the award subject to satisfaction of the Price Condition is scheduled to vest in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022. Upon the closing of the IPO, vesting of the portion of the option award subject to condition (ii) was tied only to the passage of time and the market price of the Company's securities and thus, 50% of the option award became reportable. F3 · derivative.exercise_date: (Continued from Footnote 2) The Original Form 4 failed to report the portion of the option award that became reportable upon the closing of the Company's IPO. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.